Global Information
회사소개 | 문의 | 비교리스트

T세포표면당단백질 CD3 입실론체인(T세포표면항원 T3/Leu-4 입실론체인, CD3e) : 파이프라인 리뷰

T Cell Surface Glycoprotein CD3 Epsilon Chain - Pipeline Review, H2 2019

리서치사 Global Markets Direct
발행일 2019년 11월 상품 코드 364833
페이지 정보 영문 84 Pages
가격
US $ 3,500 ₩ 4,286,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 8,572,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 12,859,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


T세포표면당단백질 CD3 입실론체인(T세포표면항원 T3/Leu-4 입실론체인, CD3e) : 파이프라인 리뷰 T Cell Surface Glycoprotein CD3 Epsilon Chain - Pipeline Review, H2 2019
발행일 : 2019년 11월 페이지 정보 : 영문 84 Pages

T세포표면당단백질 CD3 입실론체인(T세포표면항원 T3/Leu-4 입실론체인, CD3e)을 표적으로 한 치료제 개발 상황에 대해 분석했으며, 개발 단계, 약제 표적, 작용기서, 투여 경로 및 분자 종류별 분석, 치료제 개발에 참여하고 있는 기업 개요, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.

서론

  • 조사 범위

T세포표면당단백질 CD3 입실론체인(T세포표면항원 T3/Leu-4 입실론체인, CD3e) 개요

치료제 개발

T세포표면당단백질 CD3 입실론체인(T세포표면항원 T3/Leu-4 입실론체인, CD3e) : 개발중인 제품 - 개발 단계별

T세포표면당단백질 CD3 입실론체인(T세포표면항원 T3/Leu-4 입실론체인, CD3e) : 개발중인 제품 - 치료 분야별

T세포표면당단백질 CD3 입실론체인(T세포표면항원 T3/Leu-4 입실론체인, CD3e) : 개발중인 제품 - 적응증별

T세포표면당단백질 CD3 입실론체인(T세포표면항원 T3/Leu-4 입실론체인, CD3e) : 파이프라인 제품 개요

  • 후기 단계 제품
  • 초기 단계 제품

T세포표면당단백질 CD3 입실론체인(T세포표면항원 T3/Leu-4 입실론체인, CD3e) : 기업에서 개발중인 제품

T세포표면당단백질 CD3 입실론체인(T세포표면항원 T3/Leu-4 입실론체인, CD3e) : 대학/기관에서 개발중인 제품

T세포표면당단백질 CD3 입실론체인(T세포표면항원 T3/Leu-4 입실론체인, CD3e) : 치료제 평가

  • 단독요법/병용요법 제품별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

T세포표면당단백질 CD3 입실론체인(T세포표면항원 T3/Leu-4 입실론체인, CD3e) 치료제 개발에 참여하고 있는 기업

  • Amgen Inc.
  • GlaxoSmithKline Plc
  • MacroGenics, Inc.
  • Tiziana Life Sciences Plc
  • Xencor, Inc.

약제 개요

T세포표면당단백질 CD3 입실론체인(T세포표면항원 T3/Leu-4 입실론체인, CD3e) : 휴지중인 프로젝트

T세포표면당단백질 CD3 입실론체인(T세포표면항원 T3/Leu-4 입실론체인, CD3e) : 주요 뉴스와 프레스 릴리스

부록

KSM 16.08.09

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Amgen Inc, H2 2019
  • Pipeline by Celgene Corp, H2 2019
  • Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
  • Pipeline by Numab Innovation AG, H2 2019
  • Pipeline by Provention Bio Inc, H2 2019
  • Pipeline by SYNIMMUNE GmbH, H2 2019
  • Pipeline by Tiziana Life Sciences Plc, H2 2019
  • Pipeline by Tolerx, Inc. (Inactive), H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019

Summary:

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) pipeline Target constitutes close to 13 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report T Cell Surface Glycoprotein CD3 Epsilon Chain - Pipeline Review, H2 2019, outlays comprehensive information on the T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - T-Cell surface glycoprotein CD3 epsilon chain also known as CD3E is a polypeptide encoded by the CD3E gene. T-cell surface glycoprotein CD3 epsilon chain interacts with TOP2B, CD3EAPand NCK2. The CD3 complex mediates signal transduction, resulting in T-cell activation and proliferation. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2, 3 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Metabolic Disorders, Gastrointestinal, Genetic Disorders, Immunology and Infectious Disease which include indications Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Multiple Sclerosis, Type 1 Diabetes (Juvenile Diabetes), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Amyotrophic Lateral Sclerosis, B-Cell Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Inflammation, Crohn's Disease (Regional Enteritis), Down Syndrome, Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), Hepatitis B, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Lymphoblastic Lymphoma, Multiple Myeloma (Kahler Disease), Nodal Marginal Zone B-Cell Lymphoma, Non-Alcoholic Steatohepatitis (NASH), Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Primary Mediastinal B-Cell Lymphoma, Prostate Cancer, Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rheumatoid Arthritis, Solid Tumor, Splenic Marginal Zone B-Cell Lymphoma, Traumatic Brain Injury and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

Furthermore, this report also reviews key players involved in T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E)
  • The report reviews T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics and enlists all their major and minor projects
  • The report assesses T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Overview
  • T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Companies Involved in Therapeutics Development
    • Amgen Inc
    • Celgene Corp
    • F. Hoffmann-La Roche Ltd
    • Numab Innovation AG
    • Provention Bio Inc
    • SYNIMMUNE GmbH
    • Tiziana Life Sciences Plc
    • Tolerx, Inc. (Inactive)
  • T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Drug Profiles
    • AMG-330 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Bispecific Monoclonal Antibodies to Target CD3, CD16 and HBsAg for HBV Infection and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Bispecific Monoclonal Antibody to Target CD3E and PSMA for Prostate Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • blinatumomab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EM-801 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • foralumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Fusion Protein to target CD3E and Cells Expressing NKG2D for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ND-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • otelixizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pasotuxizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RO-7082859 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TACSYN - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • teplizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Dormant Products
  • T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Product Development Milestones
    • Featured News & Press Releases
      • Nov 06, 2019: Roche to present on its Non-Hodgkin Lymphoma drug candidate CD20-TCB at the American Society of Hematology 2019 Annual Meeting
      • Oct 24, 2019: Provention Bio announces PRV-031 (Teplizumab) granted PRIME designation by the European Medicines Agency
      • Sep 25, 2019: Amgen stops Blincyto's Phase III paediatric ALL trials early
      • Sep 24, 2019: Provention Bio reiterates regulatory strategy for PRV-031 and announces completion of follow-on financing
      • Sep 16, 2019: Tiziana Life Sciences announces FDA approval to initiate phase I clinical trial with orally administered foralumab in healthy volunteers
      • Sep 10, 2019: Tiziana reports phase 1 clinical data demonstrating nasal treatment with foralumab was well-tolerated and produced positive trend in biomarkers of immunomodulation and anti-inflammation in healthy volunteers
      • Aug 20, 2019: Provention Bio announces key addition to its leadership team
      • Aug 05, 2019: Provention Bio announces breakthrough therapy designation for Teplizumab (PRV-031) for the prevention or delay of clinical type 1 diabetes in at-risk individuals
      • Jul 01, 2019: Tiziana Life Sciences provides update on development on Foralumab
      • Jul 01, 2019: Independent Third Party Article in New England Journal of Medicine reports on Intravenous Treatment with a Humanized Anti-CD3 mAb showing delays in progression of Type 1 Diabetes
      • Jun 24, 2019: Newly published article reporting clinical activity of orally administered OKT3, a mouse anti-CD3 monoclonal antibody, in moderate to severe ulcerative colitis patients, supports Tiziana's oral monoclonal antibody platform
      • Jun 15, 2019: Amgen announces BLINCYTO (blinatumomab) five-year overall survival data At EHA 2019
      • Jun 09, 2019: A Single course of Provention's PRV-031 (Teplizumab) delays Type 1 Diabetes Onset in High-Risk Individuals by at least two years
      • Jun 02, 2019: Amgen presented data on its investigational drug AMG 212 at ASCO 2019
      • May 29, 2019: Amgen to present on its prostate cancer drug candidate AMG 212 at 55th Annual Meeting Of The American Society Of Clinical Oncology (ASCO)
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer
Back to Top
전화 문의
F A Q